Huntleigh Advisors’s AbbVie ABBV Stock Holding History

Huntleigh Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.93M	Buy	11,653 +738	+7%	+$159K	0.41%	60
2026 Q1	$2.37M	Sell	10,915 -1,303	-11%	-$289K	0.41%	62
2025 Q4	$2.79M	Buy	12,218 +78	+0.6%	+$17.8K	0.47%	57
2025 Q3	$2.81M	Sell	12,140 -241	-2%	-$49.1K	0.48%	51
2025 Q2	$2.3M	Buy	12,381 +3,313	+37%	+$616K	0.44%	54
2025 Q1	$1.9M	Sell	9,068 -295	-3%	-$57.3K	0.32%	67
2024 Q4	$1.66M	Buy	+9,363	New	+$1.72M	0.36%	66

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Huntleigh Advisors's ABBV Position: Q2 2026 in Review

Huntleigh Advisors increased its AbbVie (ABBV) stake by 6.8% in Q2 2026, buying an estimated $159K and bringing the position to 11,653 shares worth $2.93M. The position accounts for 0.41% of the portfolio, ranked #60.

Huntleigh Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Huntleigh Advisors held 11,653 shares of AbbVie worth $2.93M as of Q2 2026.
Huntleigh Advisors bought 738 AbbVie shares in Q2 2026, an estimated $159K.
AbbVie made up 0.41% of Huntleigh Advisors's portfolio in Q2 2026, its #60 holding.
Huntleigh Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Huntleigh Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.